A PLACEBO-CONTROLLED, PHASE I, PILOT CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF ENV 2-3, A YEAST-DERIVED RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS-1, IN COMBINATION WITH MTP-PE/MF59 IN INDIVIDUALS WITH HIV INFECTION (PLACEBO PATIENTS RECEIVE MF59 EMULSION ONLY):